2S. Schade vanWestrum, et al. Intracerebral haemonrrhage after thrombolysis for ischemic stroke, Cerebrovascula~diseases 2002: 235.
3LR. Caplian, Caplan's stroke: A clinical approach: Third Edition 2000; 115-130.
4L Leonardi-Bee, et al, Symptomatic interacranial haemorrhage: relationship to dose and timing of heparin treatment and stoke severity, Cerebrovascular diseases 2002: 10.
5N. Nighoghossian, et al, Old microbleeds are a potential risk factor for cerebral bleeding after ischemic. Stroke. 2002.33: 735.
1PhilipB. Gorelick, MD, MPH, FACE Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke, 2002,33: 862-875.
2Relton JK, Rothwell N J, et al. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995,139: 4174-4177.
3Olsson AG, Pears J, McKellar J, et al. Effect ofrosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol,2001,88 (5): 504-508.
4M Steiner, M Brainin. Helicopter-assisted stroke admissions increase the rate of systemic thrombolysis (Austrian stroke registry for acute stroke units). Cerebralvascular diseases abstracts-the 11^th European Stroke Conference, 2002, May 29-June 1: 53.
5Wemer Hacke, Markku Kaste, Tom Skyhoj Olsen, Julien Bogousslavsky, Jean-MarcOrgogozo. Acute Treatment of Ischemic Stroke. Cerebral Vascular Disease,2000,10 (3): 22-33.
6Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk, 2001,8 (6): 383-390.
7Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hyperchol-esterolemia. Ann Pharmacother, 2002,36 (1): 93-101.
8Adams HP, Bendixen BH, Kapple L J, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinnical trial. Stroke, 1993,24:35-41.
9Evrard S & Bousser MG: Watershed cerebral infarcts. Sang Thrombose Vaisseau,1991, 3: 103-108.
10Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I, chnical trials. Lancet, 2001,357: 373-380.
3Gelmers H,Gtorter K,Weerdk GT,et al.A controlled trial of nimodipive in acute ischemia stroke[J].N Engl J Med,1998,318:203.
4Ghosh AK,Bradham WS,Gleaves LA,et al.Genetic deficiency of plas-minogen activator inhibitor-1 promotes cardiac fibrosis in aged mice:in-volvement of constitutive transforming growth factor-beta signaling and en-dothelial-to-mesenchymal transition[J].Circulation,2010;122(12):1200-9.
5Hnggi D,Steiger HJ.The influence of cisternal and ventricular lavage on cerebral vasospasm in patients suffering from subarachnoid hemorrhage:a-nalysis of effectiveness[J].Acta Neurochir Suppl,2011;110(2):95-8.
6Pettersen JA,Hudon ME,Hill MD.Intra-arterial thrombolysis in acute is-chemic stroke:areview of pharmacologic approaches[J].Expert Rev Car-diovas Ther,2004;(22):285.
7Teoh HL,Sharma VK,Ning C,et al.Late hemicranictomy after neurologi-cal deterioration for massive hemispheric infarction[J].Cerebrovasc Dis,2008;25(Supp l 2):164.
8Wartenberg KE,Reichelt C,Gahn G,et al.Hyperosmolar hypothermic nomrpglycemia for preventing cerebral edema after large hemispheric in-farction-an ongoing feasibility study[J].Cerebrovasc Dis,2008;25(Supp l 2):26.
